Über die chromotropen Zellen der Nebenniere vom Wasserfrosch

Zusammenfassung Aus dieser neuerlichen Untersuchung der zuerst von Stilling beschriebenen Sommerzellen ergibt sich somit als einzige Übereinstimmung in den sonst widerspruchsvollen Angaben des Schrifttums, daß sie in ihrem Vorkommen nicht auf den Sommer beschränkt sind, weshalb sie von mir nach ihrer färberischen Eigentümlichkeit als chromotrope Zellen bezeichnet werden. Da ihr isoelektrischer Punkt bei etwa p_H 5 liegt, verhalten sie sich gegenüber Farbstoffen nicht ausschließlich (acido-) oxyphil, doch sind sie auch keine Mastzellen oder überhaupt während der Entwicklung veränderte Wanderzellen, sondern eine besondere Art autochthon entstandener Nebennieren-Epithelzellen, deren Körnchen saure Polysaccharide enthalten. Ihre funktionelle Bedeutung muß erst geklärt werden. Dabei ist es besonders bemerkenswert, daß sich das Vorkommen dieser Zellen auf Rana esculenta und eine Abart von ihr sowie exotische Verwandte beschränkt, während sie bei Rana temporaria und deren nächsten Verwandten immer fehlen. Die gegenteiligen Angaben der Literatur beruhen wahrscheinlich teilweise auf unzutreffender Bestimmung der Art und im übrigen wohl auf Verwechslung mit gekörnten Wanderzellen, was besonders bei der Entwicklung zu falschen Vorstellungen führen kann.Herrn Professor Alfred Kohn in dankbarer Erinnerung gewidmet.     

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis

IntroductionSystemic sclerosis is an autoimmune disease characterized by inflammation and fibrosis of the skin and internal organs. We sought to assess the clinical and molecular effects associated with response to intravenous abatacept in patients with diffuse cutaneous systemic.MethodsAdult diffuse cutaneous systemic sclerosis patients were randomized in a 2:1 double-blinded fashion to receive abatacept or placebo over 24 weeks. Primary outcomes were safety and the change in modified Rodnan Skin Score (mRSS) at week 24 compared with baseline. Improvers were defined as patients with a decrease in mRSS of ≥30 % post-treatment compared to baseline. Skin biopsies were obtained for differential gene expression and pathway enrichment analyses and intrinsic gene expression subset assignment.ResultsTen subjects were randomized to abatacept (n = 7) or placebo (n = 3). Disease duration from first non-Raynaud’s symptom was significantly longer (8.8 ± 3.8 years vs. 2.4 ± 1.6 years, p = 0.004) and median mRSS was higher (30 vs. 22, p = 0.05) in the placebo compared to abatacept group. Adverse events were similar in the two groups. Five out of seven patients (71 %) randomized to abatacept and one out of three patients (33 %) randomized to placebo experienced ≥30 % improvement in skin score. Subjects receiving abatacept showed a trend toward improvement in mRSS at week 24 (−8.6 ± 7.5, p = 0.0625) while those in the placebo group did not (−2.3 ± 15, p = 0.75). After adjusting for disease duration, mRSS significantly improved in the abatacept compared with the placebo group (abatacept vs. placebo mRSS decrease estimate −9.8, 95 % confidence interval −16.7 to −3.0, p = 0.0114). In the abatacept group, the patients in the inflammatory intrinsic subset showed a trend toward greater improvement in skin score at 24 weeks compared with the patients in the normal-like intrinsic subset (−13.5 ± 3.1 vs. −4.5 ± 6.4, p = 0.067). Abatacept resulted in decreased CD28 co-stimulatory gene expression in improvers consistent with its mechanism of action. Improvers mapped to the inflammatory intrinsic subset and showed decreased gene expression in inflammatory pathways, while non-improver and placebos showed stable or reverse gene expression over 24 weeks.ConclusionsClinical improvement following abatacept therapy was associated with modulation of inflammatory pathways in skin.

Trial registration

ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00442611","term_id":"NCT00442611"}}NCT00442611. Registered 1 March 2007.

Electronic supplementary material

The online version of this article (doi:10.1186/s13075-015-0669-3) contains supplementary material, which is available to authorized users.     

Hermaphroditismus und Intersexualität

Zusammenfassung Es wird zunächst eine kurze Darstellung der Geschlechtsverhältnisse bei den Wirbeltieren nach dem normalen Ablauf der Entwicklung und Ergebnissen experimenteller Untersuchungen gegeben, um auf verschiedene Besonderheiten bei manchen Amphibien und Säugetieren als Grundlage für das Verständnis von Fehlbildungen beim Menschen hinzuweisen. Diese werden in Verbindung mit einem genauer beschriebenen und genetisch analysierten Fall unter Stellungnahme zu den verschiedenen Auffassungen besprochen. Die sich daraus ergebende Beurteilung der Ausbildung in männlicher und weiblicher Richtung soll das Auftreten vermittelnder Zwischenstufen ohne Annahme einer Geschlechtsumwandlung erklären und eine mehr biologische statt der bisherigen ausschlie\lich morphologischen Beurteilung anregen.     

Light Activation of Rhodopsin: Insights from Molecular Dynamics Simulations Guided by Solid-State NMR Distance Restraints

Structural restraints provided by solid-state NMR measurements of the metarhodopsin II intermediate are combined with molecular dynamics simulations to help visualize structural changes in the light activation of rhodopsin. Since the timescale for the formation of the metarhodopsin II intermediate (> 1 ms) is beyond that readily accessible by molecular dynamics, we use NMR distance restraints derived from ¹³C dipolar recoupling measurements to guide the simulations. The simulations yield a working model for how photoisomerization of the 11-cis retinylidene chromophore bound within the interior of rhodopsin is coupled to transmembrane helix motion and receptor activation. The mechanism of activation that emerges is that multiple switches on the extracellular (or intradiscal) side of rhodopsin trigger structural changes that converge to disrupt the ionic lock between helices H3 and H6 on the intracellular side of the receptor.     

Copper(II) complexes based on a new chelating 4-(3,5-diphenyl-1H-pyrazol-1-yl)-6-(piperidin-1-yl)pyrimidine ligand: Synthesis and crystal structures. Lone pair-π, C-H···π, π-π and C-H···A (A = N, Cl) non-covalent interactions

A new bidentate chelating pyrazolylpyrimidine ligand bearing a strong electron-donating substituent, i.e. 4-(3,5-diphenyl-1H-pyrazol-1-yl)-6-(piperidin-1-yl)pyrimidine (L) (Scheme 1), has been synthesized and used to obtain the copper(II) complexes by reaction with CuCl₂. The molar ratio Cu:L = 1:2 leads to isolation of a complex having CuL₂Cl₂ empirical formula, while the molar ratio Cu:L = 1:1 gives a complex with CuLCl₂ empirical formula. The crystal structure of L as well as the structures of both complexes were studied by single crystal X-ray diffraction. The crystal structure of CuL₂Cl₂ compound is formed by trans-[CuL₂Cl₂] mononuclear molecules. Surprisingly, in contrast to the previous compound having molecular structure, the crystal structure of CuLCl₂ consists of mononuclear [CuL₂Cl]⁺ complex cations and dinuclear [Cu₂Cl₆]²⁻ anions. Thus, formula of CuLCl₂ complex can be represented as [CuL₂Cl]₂[Cu₂Cl₆]. In both complexes molecules of L adopt bidentate chelating coordination mode through N² atom of pyrazole and N³ atom of pyrimidine rings forming five-membered CuN₃C metallocycles. Owing to C-H···N interactions and π-π-stacking L molecules form 2D network. In the structure of trans-[CuL₂Cl₂] there exist double lone pair(N(piperidine))-π(pyrimidine) interactions and C-H···Cl contacts resulting in the formation of 1D chains. Layered 2D structure of [CuL₂Cl]₂[Cu₂Cl₆] results from C-H···Cl, C-H···π and double lone pair(Cl([CuL₂Cl]⁺ complex cation)-π(pyrimidine) interactions.